Resumo

ROQUE-GARCIA, Wilfredo. Refractory primary immune thrombocytopenia: treatment options. Rev Cubana Hematol Inmunol Hemoter [online]. 2012, vol.28, n.4, pp. 327-346. ISSN 0864-0289.

The primary immune thrombocytopenia (PIT) is an acquired autoimmune disorder characterized by transient or persistent decreased platelet count with increased risk of bleeding. The chronic form of this disease primarily affects adults. Since spontaneous remissions are rare, patients usually are treated with steroids from the start. Approximately one third of the cases does not respond to steroid regimens; the second-line treatment is splenectomy, achieving the highest cure rates. However, between 10 to 30% of patients do not respond to spleen surgical removal, which is the group of patients with refractory chronic PIT. There is no evidence on whether this therapeutic regimen is most effective in these cases, so the treatment remains empirical. In this paper, various treatment options that can be used in refractory chronic PIT, the action mechanism of drugs, doses and more frequent adverse effects were reviewed.

Palavras-chave : primary immune thrombocytopenia; treatment.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )